Clinical Asthma Exacerbation

Even patients with mild asthma sometimes experience acute exacerbations that require visits to the ED or hospitalization, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

SAN DIEGO — Few patients are evaluated based on all seven endpoints of guidelines indicating complete asthma remission, according to a poster presented at the American Thoracic Society International Meeting.

Patients with asthma exacerbations and elevated blood eosinophils and fractional exhaled nitric oxide saw fewer exacerbations with lebrikizumab, according to a study published in the Journal of Allergy and Clinical Immunology: In Practice.

HONOLULU — Patients with well-controlled asthma who use dupilumab may tolerate a reduction in the frequency of their doses from every 2 weeks to every 4 weeks, according to a poster presented at the CHEST Annual Meeting.

HONOLULU — Children with uncontrolled moderate to severe asthma experienced fewer severe exacerbations requiring systemic corticosteroids when treated with dupilumab, according to a poster presented at the CHEST Annual Meeting.

HONOLULU — Analyzing real-world digital inhaler data using expert-consensus thresholds on reliever medication use helped find medication overuse and may predict exacerbations, according to an abstract presented at the CHEST Annual Meeting.

Many patients with moderate to severe asthma failed to use inhaled corticosteroids in addition to a short-acting beta 2 agonist as a rescue to prevent exacerbations, according to a study published in Annals of Allergy, Asthma & Immunology.

Mepolizumab, reslizumab and dupilumab were equally effective in controlling symptoms among patients with eosinophilic severe asthma, according to a study published in Annals of Allergy, Asthma & Immunology.

Tezepelumab reduced health care utilization for asthma across all outcomes measured, as well as the severity of exacerbations that required hospitalizations, according to a study published in Annals of Allergy, Asthma & Immunology.

The use of an inhaled corticosteroid, long-acting beta 2 agonist and long-acting muscarinic antagonist improved asthma outcomes compared with use of just two of those medications, according to a study published in Respiratory Medicine.